Amoéba

Regulatory Filings • Mar 31, 2023

Amoéba announces its collaboration with Nissan Chemical Corporation for the biocontrol application.

Lyon (France), March 31st, 2023– 08h30 - AMOÉBA (FR0011051598 – ALMIB) an industrial biotech in pre-commercialization* specialized in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, announces that, in the framework of a Material Transfer Agreement, Nissan Chemical Corporation has started a performance evaluation study of the mixture of one of its products with an Amoéba biocontrol experimental product.

The aim of this evaluation is to determine the performance in controlling grapevine downy mildew of the combination of Nissan Leimay® product (suspension concentrate at 200 g/l amisulbrom) and Amoéba AXP12 experimental product (suspension concentrate at 215 g/l lysate of Willaertia magna C2c Maky),

This extemporaneous mixture was tested in two trials against grapevine downy mildew in Italy, in conditions of high disease pressure. Ten applications at 7-day intervals were made.

The combination Leimay®+ AXP12, tested at a reduced dose of both products, was very efficient on leaves and bunches. It is superior to Leimay® and AXP12 used alone at their full dose, which could allow a reduction in the dose of either or both products.

Moreover, the performance of this mixture is significantly better than the reference product of the trials, copper hydroxide (at the rate of 200 g active ingredient/ha/treatment).

These results support the continuation of the experiment in 2023.

About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of microbiological risk in the water, plant protection and health sectors. Based on the natural properties of the amoeba Willaertia magna C2c Maky, our biological solution is a viable alternative to the chemical products widely used in the industry today. Amoeba is currently focused on the closed system industrial cooling tower market in the United States estimated at €200 million (1) and on the global biocontrol market for plant protection estimated at €3 billion (2), out of a global market for chemical fungicides estimated at €21 billion (3). The commercialization of the associated biocides and phytosanitary products is subject to local regulatory approvals.

*At the end of 2022, Amoeba obtained approval of its active substance for biocidal use in closed cooling system and for biocontrol use in the United States. The substance has also been recommended for biocontrol use in Europe by the Austrian authority in the same year. The company is currently in a pre-commercialization phase for biocidal and plant protection applications and is expected to market its products by 2025. Founded in 2010

and based in Chassieu (Lyon, France), Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit www.amoeba-nature.com.

(1): Amoéba data (2): IBMA data (3): Amoeba data

Contacts :

Amoéba Valérie FILIATRE Deputy General Manager +33 4 26 69 16 00 v.filiatre@amoeba-nature.com Calyptus Investor & Press Relations Nicolas HELIN / Mathieu CALLEUX +33 1 53 65 37 90 /91

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of AMOEBA to be materially different from such forwardlooking statements.